Journal Article

DKFZ-2026-01163

http://join2-wiki.gsi.de/foswiki/pub/Main/Artwork/join2_logo100x88.png CD155-CD96 keeps quiescent persister tumor cells in check.

Gorol, J. M. ; Greten, F. R.DKFZ*

2026
Cell Press Cambridge, Mass.

Abstract: In this issue of Developmental Cell, Geng et al. show that quiescent persister tumor cells (PTCs) in colorectal cancer are enriched after neoadjuvant chemotherapy and exhibit increased expression of CD155, leading to dysfunction of tumor-infiltrating CD96+CD8+ T cells. Anti-tumor activity can be restored through CD96-targeted monoclonal antibody therapy.

Keyword(s): Humans (MeSH) ; Antigens, CD: metabolism (MeSH) ; Colorectal Neoplasms: drug therapy (MeSH) ; Colorectal Neoplasms: metabolism (MeSH) ; Colorectal Neoplasms: pathology (MeSH) ; Colorectal Neoplasms: immunology (MeSH) ; CD8-Positive T-Lymphocytes: immunology (MeSH) ; Antigens, CD ; CD96 antigen

Note: Preview

---

Contributing Institute(s):

1. DKTK Koordinierungsstelle Frankfurt (FM01)

Research Program(s):

1. 899 - ohne Topic (POF4-899) (POF4-899)

Appears in the scientific report 2026

---

Database coverage:
; BIOSIS Previews ; Biological Abstracts ; Clarivate Analytics Master Journal List ; Current Contents - Life Sciences ; Ebsco Academic Search ; Essential Science Indicators ; IF >= 10 ; JCR ; SCOPUS ; Science Citation Index Expanded ; Web of Science Core Collection

---